Verasone - Diceros Therapeutics
Alternative Names: Verasone™Latest Information Update: 15 Jan 2024
At a glance
- Originator Diceros Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Rhinosinusitis
Most Recent Events
- 06 Dec 2023 Verasone is available for licensing as of 06 Dec 2023. https://www.dicerostherapeutics.com/partnerships
- 06 Dec 2023 Diceros Therapeutics has patent protection for Verasone™ (Diceros Therapeutics Pipeline, December2023)
- 28 Nov 2023 Preclinical trials in Rhinosinusitis in USA (Intranasal)